Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Uterine Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 5Pemetrexed 3Paclitaxel 3Gemcitabine 3Docetaxel 3Brachytherapy 3pembrolizumab 2Topotecan 2Saline Solution 2Radiotherapy 2Radiation 2FANG vaccine 2Everolimus 2Doxorubicin 2Cisplatin 2Carboplatin 2CP protocol 2temsirolimus 1selinexor 1osimertinib 1niraparib 1fosaprepitant 1ferumoxtran-10 1ferrous fumarate 1durvalumab 1cobimetinib 1atezolizumab 1alovudine 1Vitamin D 1Uterine Artery Embolization 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uterine Neoplasms × 4-hydroxy-N-desmethyltamoxifen × Clear all
NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡